Therapy of advanced non-small-cell lung cancer with irinotecan and gemcitabine in combination

Juliana Ribeiro de Freitas, Caio M. Rocha-Lima

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Non-small-cell lung cancer is the leading cause of cancer-related deaths in the United States. Chemotherapy has been shown to improve survival and quality of life in patients with advanced disease when compared to best supportive care. Of the commonly used therapies, platinum in combination with gemcitabine, taxanes, and vinorelbine offers superior activity to single-agent platinum or older platinum combinations. In addition, single-agent gemcitabine or single-agent paclitaxel has resulted in lower survival compared to each in combination with carboplatin in 2 recently reported phase III trials. However, among themselves new doublets have shown no improvement in survival, and treatment has traditionally been chosen based on convenience and toxicity rather than efficacy. The combination of gemcitabine and irinotecan has demonstrated promising results in preclinical studies. In this review, the data available on the combination of gemcitabine and irinotecan in phase I and phase II trials are discussed.

Original languageEnglish (US)
Pages (from-to)S26-S29
JournalClinical Lung Cancer
Issue numberSUPPL. 1
StatePublished - Nov 2002


  • Antimetabolite
  • Nonplatinum combinations
  • Second-line chemotherapy
  • Topoisomerase I inhibitor

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Therapy of advanced non-small-cell lung cancer with irinotecan and gemcitabine in combination'. Together they form a unique fingerprint.

Cite this